Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max S Topp

Showing results (81-90 of 122) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemiaMax S Topp, Nicola Gökbuget, Gerhard Zugmaier, et al.
Blood Advances|August 21, 2023
Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry studyMaria-Luisa Schubert, Wolfgang A Bethge, Francis A Ayuk, et al.
British Journal of Haematology|November 14, 2021
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i)Sarah Gillessen, Andreas Hüttmann, Vladan Vucinic, et al.
Blood Advances|September 2, 2021
Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MMMarietta S Truger, Johannes Duell, Xiang Zhou, et al.
Journal for Immunotherapy of Cancer|March 22, 2024
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphomaJurriaan Brouwer-Visser, Nathalie Fiaschi, Raquel P Deering, et al.
Blood|January 9, 2025
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 studyMax S Topp, Matthew Matasar, John N Allan, et al.
The Lancet. Haematology|April 3, 2022
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trialRajat Bannerji, Jon E Arnason, Ranjana H Advani, et al.
American Journal of Cancer Research|July 15, 2024
Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphomaTom van Meerten, John Kuruvilla, Kevin W Song, et al.
Haematologica|February 13, 2023
General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemiaNicola Gökbuget, Kristina Ihrig, Michael Stadler, et al.
European Journal of Immunology|July 28, 2023
Enolase 1 of Candida albicans binds human CD4<sup>+</sup> T cells and modulates naïve and memory responsesMuhammad Daud, Prasad Dasari, Marion Adelfinger, et al.
Pageof 13

Showing results (81-90 of 122) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemiaMax S Topp, Nicola Gökbuget, Gerhard Zugmaier, et al.
Blood Advances|August 21, 2023
Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry studyMaria-Luisa Schubert, Wolfgang A Bethge, Francis A Ayuk, et al.
British Journal of Haematology|November 14, 2021
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i)Sarah Gillessen, Andreas Hüttmann, Vladan Vucinic, et al.
Blood Advances|September 2, 2021
Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MMMarietta S Truger, Johannes Duell, Xiang Zhou, et al.
Journal for Immunotherapy of Cancer|March 22, 2024
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphomaJurriaan Brouwer-Visser, Nathalie Fiaschi, Raquel P Deering, et al.
Blood|January 9, 2025
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 studyMax S Topp, Matthew Matasar, John N Allan, et al.
The Lancet. Haematology|April 3, 2022
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trialRajat Bannerji, Jon E Arnason, Ranjana H Advani, et al.
American Journal of Cancer Research|July 15, 2024
Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphomaTom van Meerten, John Kuruvilla, Kevin W Song, et al.
Haematologica|February 13, 2023
General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemiaNicola Gökbuget, Kristina Ihrig, Michael Stadler, et al.
European Journal of Immunology|July 28, 2023
Enolase 1 of Candida albicans binds human CD4<sup>+</sup> T cells and modulates naïve and memory responsesMuhammad Daud, Prasad Dasari, Marion Adelfinger, et al.
Pageof 13